Waters Corporation · NYSE:WAT

Waters — Technical Presentation (2013)

79 slides from Waters's technical presentation, 2013

  1. Slide 1: Peptide Mapping 101: Essential Tools for Effective Development and Characterization

    Slide 1: Peptide Mapping 101: Essential Tools for Effective Development and Characterization

    Thank you for joining us! The Webinar will begin shortly… Peptide Mapping 101: Essential Tools for Effective Development and Characterization Part 1:Introduction to Peptide Mapping Stephan M. Koza, Ph. D. Principal Applications Chemist Waters Technologies Corporation ©2013 Waters Corporation 1

  2. Slide 2: Friendly Reminders

    Slide 2: Friendly Reminders

    Friendly Reminders… We will have LIVE Technical Support available to address your questions. Please use text chat functionality to submit questions during the Webinar. Upon conclusion, follow up information will be available: http://www.waters.com/Aug20 Recorded version of today’s presentation Copie

  3. Slide 3: Agenda

    Slide 3: Agenda

    Agenda What is Peptide Mapping and Why Do It? Protein Digestion Peptide Separations ©2013 Waters Corporation 3

  4. Slide 4: What is Peptide Mapping?

    Slide 4: What is Peptide Mapping?

    What is Peptide Mapping? For biotherapeutic proteins and peptides peptide mapping is: The chemical or enzymatic treatment of a protein to produce peptide fragments Separation and identification of these fragments in a reproducible manner In-depth analysis that can identify minor and even isobaric di

  5. Slide 5: Uses of Peptide Mapping

    Slide 5: Uses of Peptide Mapping

    Uses of Peptide Mapping Proteomics Studies Protein Biopharmaceutical Analysis – Structural characterization o Pattern conforms to primary structure o Used with MS for primary structure determination o Non-Reduced Mapping for Disulfide Bond Assignment – Protein modification o Identify post-translatio

  6. Slide 6: Biopharmaceutical Classes That Use Peptide Mapping Methods

    Slide 6: Biopharmaceutical Classes That Use Peptide Mapping Methods

    Biopharmaceutical Classes That Use Peptide Mapping Methods Peptides/Proteins derived through recombinant DNA-based processes – Insulin Diabetes – Erythropoietin Cancer – Monoclonal antibodies derived by recombinant DNA processes, and their derivatives o Herceptin Cancer Protein Conjugates – ADC – PE

  7. Slide 7: Why Do We Develop Peptide Maps for Biotherapeutic Proteins?

    Slide 7: Why Do We Develop Peptide Maps for Biotherapeutic Proteins?

    Why Do We Develop Peptide Maps for Biotherapeutic Proteins? Guidance for Industry Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products 1. Structural Characterization and Confirmation (6.1.1) d. Peptide map Selective fragmentation of the product into di

  8. Slide 8: Agenda

    Slide 8: Agenda

    Agenda What is Peptide Mapping and Why Do It? Protein Digestion Peptide Separations On to Part II ©2013 Waters Corporation 8

  9. Slide 9: Enzymes and Chemistries for Protein Digestion

    Slide 9: Enzymes and Chemistries for Protein Digestion

    Enzymes and Chemistries for Protein Digestion EUROPEAN PHARMACOPOEIA 5.0, 2.2.55. PEPTIDE MAPPING ©2013 Waters Corporation 9

  10. Slide 10: Enzymes and Chemistries for Protein Digestion

    Slide 10: Enzymes and Chemistries for Protein Digestion

    Enzymes and Chemistries for Protein Digestion EUROPEAN PHARMACOPOEIA 5.0, 2.2.55. PEPTIDE MAPPING Trypsin, Lys-C,and Asp-N are most commonly used and can provide high fidelity digestions for reproducible peptide maps. ©2013 Waters Corporation 10

  11. Slide 11: In silico Digestion Tools for Selecting an Enzyme: MassLynx

    Slide 11: In silico Digestion Tools for Selecting an Enzyme: MassLynx

    In silico Digestion Tools for Selecting an Enzyme (or Chemical):MassLynx Chemical):MassLynx Protein/Peptide Editor ©2013 Waters Corporation 11

  12. Slide 12: In silico Digestion Tools for Selecting an Enzyme

    Slide 12: In silico Digestion Tools for Selecting an Enzyme

    In silico Digestion Tools for Selecting an Enzyme (or Chemical) • Trypsin results in 2 amino acids and 1 di-peptide, Lys-C might be a better choice as it generates 3 manageable peptides • Further digestion would be needed to assign disulfide bonds in this example ©2013 Waters Corporation 12

  13. Slide 13: Flow Chart of Peptide Mapping

    Slide 13: Flow Chart of Peptide Mapping

    Flow Chart of Peptide Mapping Protein (e.g. antibody) Denaturation, Disulfide Reduction/Alkylation, Buffer Exchange Enzymatic Digestion (e.g. Trypsin) Peptide Map Analysis UPLC/ UV UPLC/ MS UPLC/ MS/MS UPLC/ MSE ©2013 Waters Corporation 13

  14. Slide 14: What's RapiGest SF

    Slide 14: What's RapiGest SF

    What’s RapiGest™ SF Anionic detergent that improves solubility and digestion of many proteins for improved enzymatic digests. Unlike conventional denaturants, RapiGest SF does not inhibit enzyme activities so it can reduce digestion times and reduces the amount of enzyme used. It does not cause prot

  15. Slide 15: Reproducible Peptide Mapping

    Slide 15: Reproducible Peptide Mapping

    Reproducible Peptide Mapping Pitfalls of Peptide Mapping – that can affect robustness, reproducibility and accuracy: – Sample preparation o Incomplete digestion o Non-reproducible digestion conditions o Non-specific cleavages (over-digestion) o Enzyme lot-to-lot variability (activity units or mass?)

  16. Slide 16: Agenda

    Slide 16: Agenda

    Agenda What is Peptide Mapping and Why Do It? Protein Digestion Peptide Separations On to Part II ©2013 Waters Corporation 16

  17. Slide 17: Peptide Separations

    Slide 17: Peptide Separations

    Peptide Separations Column Selection – Ethylene Bridged Hybrid (BEH) Particle Technology – UPLC vs HPLC – Charged Surface Hybrid Technology Fine Tuning Your Separation ©2013 Waters Corporation 17

  18. Slide 18: Ethylene Bridged Hybrid - BEH Technology

    Slide 18: Ethylene Bridged Hybrid - BEH Technology

    Ethylene Bridged Hybrid - BEH Technology™ U.S. Patent No. 6,686,035 B2 and others patent pending Bridged Ethanes In Silica Matrix Organo Silica Hybrid Particles – pH stability – Reduced ionic interactions – Basis of Peptide Separation Technology EtO CH2 CH2 OEt OEt O Si O Et Si Si EtO OEt EtO O O 4

  19. Slide 19: Small Particle Size

    Slide 19: Small Particle Size

    Small Particle Size Mobile Phase 1500 Da Peptide Peptides 2 3.5 µm Porous Particle H (mm) Adsorption Equilibria Diffusion-related band broadening 1 Diffusion distances decrease 1.7 µm – Reduced Eddy diffusion, A-Term – Improved mass transfer kinetics, C-Term Column efficiency 40 400 Narrower peaks µ

  20. Slide 20: Why UPLC for peptide mapping

    Slide 20: Why UPLC for peptide mapping

    Why UPLC® for peptide mapping More resolution even using a shorter gradient HPLC 2.1 x 300 mm, 7.0e-2 3.5 µ 90 min 6.0e-2 5.0e-2 AU 4.0e-2 3.0e-2 2.0e-2 1.0e-2 Time 30.00 35.00 40.00 45.00 50.00 55.00 60.00 65.00 70.00 75.00 80.00 85.00 90.00 1.0e-1 UPLC 2.1 x 150 mm, 9.0e-2 1.7 µ 55 min 8.0e-2 7.0e

  21. Slide 21: Charged Surface Hybrid (CSH) Technology

    Slide 21: Charged Surface Hybrid (CSH) Technology

    Charged Surface Hybrid (CSH) Technology patent pending Charged Surface Hybrid (CSH) Technology and Its Use in Liquid Chromatography. P.C. Iraneta, K.D. Wyndham, D.R. McCabe, and T.H. Walter Waters White Paper 720003929EN 2011 Expands upon the robust BEH particle technology CSH130 C18 = BEH130 base p

  22. Slide 22: Peak Capacity

    Slide 22: Peak Capacity

    Peak Capacity Peak Capacity = – The number of peaks that can be separated within a retention window Neue, U. D., J Chromatogr A 2005, 1079 (1-2), 153-61. – The best metric for determining the quality of gradient separations 100% 9 peaks Peak Height could resolve 2.35σ wh 50% ~300-400 4σ 13.4% w4σ 0%

  23. Slide 23: A Novel Column Chemistry: CSH130 C18

    Slide 23: A Novel Column Chemistry: CSH130 C18

    A Novel Column Chemistry: CSH130 C18 (0.1% TFA) Competitor’s BEH130 C18 “Industry Standard” C18 Porous (130Å) 1.7 µm Porous (300Å) 5 µm 2.1 x 150 mm 2.1 x 250 mm UV absorbance (214 nm) 10 50 10 50 Time (min) 10 20 Time (min) 30 40 50 Competitor’s CSH130 C18 Superficially Porous Porous (130Å) 1.7 µm

  24. Slide 24: Peak Capacity - FA vs TFA

    Slide 24: Peak Capacity - FA vs TFA

    Peak Capacity - FA vs TFA 370 320 270 c,4σ Pc,4 220 170 Competitor’s “Industry Standard” Silica C18 5 µm 2.1 x 250 mm 120 70 20 0.00 0.05 0.10 TFA FA Percent TFA % TFA 0.00 0.05 0.10 % FA 0.10 0.05 0.00 ©2013 Waters Corporation 24

  25. Slide 25: Peak Capacity - FA vs TFA

    Slide 25: Peak Capacity - FA vs TFA

    Peak Capacity - FA vs TFA 370 320 270 BEH130 C18 1.7 µm 2.1 x 150 mm c,4σ Pc,4 220 170 Competitor’s “Industry Standard” Silica C18 5 µm 2.1 x 250 mm 120 70 20 0.00 0.05 0.10 TFA FA Percent TFA % TFA 0.00 0.05 0.10 % FA 0.10 0.05 0.00 ©2013 Waters Corporation 25

  26. Slide 26: Peak Capacity - FA vs TFA

    Slide 26: Peak Capacity - FA vs TFA

    Peak Capacity - FA vs TFA 370 320 Competitor’s SPP “Peptide” C18 1.7 µm 2.1 x 150 mm 270 BEH130 C18 1.7 µm 2.1 x 150 mm c,4σ Pc,4 220 170 Competitor’s “Industry Standard” Silica C18 5 µm 2.1 x 250 mm 120 70 20 0.00 0.05 0.10 TFA FA Percent TFA % TFA 0.00 0.05 0.10 % FA 0.10 0.05 0.00 ©2013 Waters Co

  27. Slide 27: Peak Capacity - FA vs TFA

    Slide 27: Peak Capacity - FA vs TFA

    Peak Capacity - FA vs TFA CSH130 C18 1.7 µm 370 2.1 x 150 mm 320 Competitor’s 20% SPP “Peptide” C18 1.7 µm 2.1 x 150 mm 270 90% BEH130 C18 1.7 µm 2.1 x 150 mm c,4σ Pc,4 220 170 Competitor’s “Industry Standard” Silica C18 5 µm 2.1 x 250 mm 120 70 20 0.00 0.05 0.10 TFA FA Percent TFA % TFA 0.00 0.05 0

  28. Slide 28: Loadability

    Slide 28: Loadability

    Loadability Attribute – how much analyte can be loaded before peak shape deteriorates Low Mass Load Typical Mass Load 0.6 µg of mixture 0.6 6 µg of mixture 6 µg ofMass mixture Lowµg ofLoad mixture 450 450 CSH C18 B Mass (Equivalent to ~ 4.5 µg of a mAb) CSH C18 A High Load (Equivalent to ~ 45 µg of

  29. Slide 29: Which Column do I choose CSH130 C18 or BEH130 C18?

    Slide 29: Which Column do I choose CSH130 C18 or BEH130 C18?

    Which Column do I choose CSH130 C18 or BEH130 C18? 2E+6 0.1% FA BEH130 BEH C18 C18 1.7 1.7 µmµm Pc,4σ = 399 Pc,4σ = 399 Intensity 1E+6 0E+0 0 10 20 30 40 50 60 0 10 20 30 40 50 60 2E+6 Time(min) CSH130 CSH C18C18 1.71.7 µmµm Intensity 1E+6 Pc,4σP= 532 c,4σ = 532 0E+0 0 10 20 30 40 50 60 Time(min) ©2

  30. Slide 30: LC-MS Retention and Selectivity

    Slide 30: LC-MS Retention and Selectivity

    LC LC--MS Retention and Selectivity 1E+6 BEH130 C18 T3 SVYDSR T5 GVFR T12 ANIDVK T19 HLADSK More positive T5/ T40 T12 T19 T10 GVLHAVK charge T3 T10 T40 IATAIEK 0E+0 5.5 6.5 7.5 8.5 9.5 10.5 11.5 12.5 Time(min) 1E+6 CSH130 C18 T5/ T19 T12 T40 T10 T3 0E+0 5.5 6.5 7.5 8.5 9.5 10.5 11.5 12.5 13.5 Time(m

  31. Slide 31: UPLC and HPLC

    Slide 31: UPLC and HPLC

    UPLC and HPLC CSH130 C18 High peak capacity separations not limited to UPLC 2.1 x150 mm 1.0 1.0 0.1 % FA 0.1 % TFA 0.8 0.8 0.6 ~8000 0.6 1.7 µm psi A214 A214 0.4 0.4 0.2 0.2 0.0 Method 0.0 10 20 30 40 50 10 20 30 40 50 Transfer 1.0 Time (min) Time (min) 1.0 0.8 0.8 0.6 ~3000 0.6 2.5 µm XP psi A214 A

  32. Slide 32: UPLC and HPLC

    Slide 32: UPLC and HPLC

    UPLC and HPLC CSH130 C18 High peak capacity separations not limited to UPLC 2.1 x150 mm 1.0 1.0 0.1 % FA 0.1 % TFA 0.8 0.8 0.6 ~8000 0.6 1.7 µm psi A214 A214 CSH130 C18 Peptide Separation 0.4 0.4 Technology Columns 0.2 0.2 Available 0.0 Now: Upcoming: Method 0.0 Analytical Columns Nano (75, 20150, T

  33. Slide 33: Three Outstanding Peptide Separation Technology Columns

    Slide 33: Three Outstanding Peptide Separation Technology Columns

    Three Outstanding Peptide Separation Technology Columns Peptide/Protein kDa 1 Bradykinin 1.1 1.2 2 2 Renin Substrate 1.8 CSH130 C18 1.7 µm 3 Ubiquitin 8.6 1 5 Cytochrome C 4 12.4 0.8 (Equine) Insulin 1 A214 0.6 5 5.7 (Bovine) 0.4 3 6 6 Melittin 2.8 0.2 4 130 Å 0 1.2 10 15 20 25 30 35 40 45 50 BEH130

  34. Slide 34: New Addition to the Suite of Waters Peptide Separation Technology

    Slide 34: New Addition to the Suite of Waters Peptide Separation Technology

    New Addition to the Suite of Waters Peptide Separation Technology Peptide Separation Technology – Peptide C18 Columns – QC Tested with Digests BEH Technology – BEH130 C18 and BEH300 C18 – Outstanding Performance for Most Applications – Two Pore Sizes – Particle Sizes: 1.7 µm, 3.5 µm, 5 µm – Analytic

  35. Slide 35: All Waters Peptide Separation Columns are Quality Control Tested

    Slide 35: All Waters Peptide Separation Columns are Quality Control Tested

    All Waters Peptide SeparationColumns are Quality Control Tested with Tryptic Digest of Cytochrome c CSH130 C18 0.1 % Formic Acid ©2013 Waters Corporation 35

  36. Slide 36: Fine Tuning Your Separation

    Slide 36: Fine Tuning Your Separation

    Fine Tuning Your Separation Parameters that Influence Selectivity – Ion Pairing Reagent (TFA, HFBA, etc.) and Concentration – Organic Eluent (MeCN, MeOH, IPA) – Column Temperature – Gradient Slope/Column Length Peak Tracking – Ideally using LC-MS can expedite separation optimization – Make several i

  37. Slide 37: Method Optimization: Gradient Slope

    Slide 37: Method Optimization: Gradient Slope

    Method Optimization: Gradient Slope Rate of Change 0.75%/ col. vol. * % * * 1 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 Rate of Change * 1.5%/ col. vol. * % * 1 Time 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 ©2013 Waters Corporation 37

  38. Slide 38: Why Does This Switch in Elution Order Occur?

    Slide 38: Why Does This Switch in Elution Order Occur?

    Why Does This Switch in Elution Order Occur? Elution at Higher % MeCN w/ Steeper Gradient Log k Elution at Lower % MeCN w/ Shallower Gradient % MeCN Adapted from: Spicer, V., Grigoryan, M., Gotfrid, A., Standing, K. G., & Krokhin, O. V. (2010). Predicting retention time shifts associated with variat

  39. Slide 39: Gradient Slope and Segmented Gradients

    Slide 39: Gradient Slope and Segmented Gradients

    Gradient Slope and Segmented Gradients Changes in gradient slope should occur in regions of separation where there are no peaks of interest Potential selectivity differences should be tracked Approach could also be used to generate a focused gradient if only specific peptides are of interest ©2013 W

  40. Slide 40: CSH130 C18 Useful Current Literature/Resources

    Slide 40: CSH130 C18 Useful Current Literature/Resources

    CSH130 C18 Useful Current Literature/Resources http://pubs.acs.org/doi/abs/10.1021/ac401481z Previously recorded webinar available: http://www.waters.com/waters/promotionDetail.htm?id=134727909 Recent Application Notes Increasing Peak Capacity in Reversed Phase Peptide Separations with Charged Surfa

  41. Slide 41: End of Part 1

    Slide 41: End of Part 1

    End of Part 1 ©2013 Waters Corporation 41

  42. Slide 42: Part 2 - Gaining Efficiency: Instrumentation and Informatics Platforms

    Slide 42: Part 2 - Gaining Efficiency: Instrumentation and Informatics Platforms

    Part 2 - Gaining Efficiency: Instrumentation and Informatics Platforms for Peptide Mapping Asish Chakraborty, Ph.D Asish_Chakraborty@waters.com ©2013 Waters Corporation 42

  43. Slide 43: A History of Relieving the Pressure on Analysts

    Slide 43: A History of Relieving the Pressure on Analysts

    A History of Relieving the Pressure on Analysts … Sample Sample Data Report Acquisition Generation Preparation Analysis Generation Chemistries Instrumentation and Informatics Automation Report Sample Generation Data Analysis Generation Report Sample Generation Generation Sample Now It Becomes Genera

  44. Slide 44: Performance and Usability through Engineered Simplicity

    Slide 44: Performance and Usability through Engineered Simplicity

    Performance and Usability through Engineered Simplicity Automatically ensuring the system is ready to run ©2013 Waters Corporation 44

  45. Slide 45: Automating batch processing, annotation, and comparison tools in BiopharmaLynx

    Slide 45: Automating batch processing, annotation, and comparison tools in BiopharmaLynx

    Automating batch processing, annotatation, and comparison tools in BiopharmaLynxTM increases productivity First shown at WCBP 2007 Meeting ©2013 Waters Corporation 45

  46. Slide 46: Biopharmaceutical Platform Solution with UNIFI 1.7

    Slide 46: Biopharmaceutical Platform Solution with UNIFI 1.7

    Biopharmaceutical Platform Solution with UNIFI 1.7 An analytical system for biotherapeutic analysis integrating UPLC/UV and UPLC/MS Intact Protein Mass Peptide Xevo G2-S QTof Mapping ACQUITY Biopharmaceutical UPLC Platform Solution H-Class & DDA (Peptide & Glycan) H-class BIO Released Glycan GU + Ma

  47. Slide 47: Deploy high resolution analytics across a biotherapeutic organization

    Slide 47: Deploy high resolution analytics across a biotherapeutic organization

    Deploy high resolution analytics across a biotherapeutic organization Few Regulatory GxP Labs compliance issues Compliance Discovery Development Production QC/QA Post-Approval Characterization Monitoring Release ©2011 Waters Corporation 47

  48. Slide 48: The Biopharmaceutical Workgroup

    Slide 48: The Biopharmaceutical Workgroup

    The Biopharmaceutical Workgroup Intact Mass, Peptide Mapping Released Glycan Analysis Office PC Office PC Lab PC UPLC-TUV- Lab PC UPLC-FLR- Xevo G2-S Xevo G2-S Office PC Lab Network LND Device (LND) LABORATORY NETWORK Lab PC LND Lab PC LND UPLC-TUV UPLC-TUV UPLC-FLR UPLC-FLR Data Processing & Databa

  49. Slide 49: UNIFI Meets the Biopharmaceutical Industry's Global Reach

    Slide 49: UNIFI Meets the Biopharmaceutical Industry's Global Reach

    UNIFI™ Meets the Biopharmaceutical industry’s Global reach A Scientific management system for the global nature of the Biopharmaceutical business ©2013 Waters Corporation 49

  50. Slide 50: Peptide Mapping in UNIFI

    Slide 50: Peptide Mapping in UNIFI

    Peptide Mapping in UNIFITM Advanced Reporting Capabilities in a GxP-ready Environment ©2013 Waters Corporation 50

  51. Slide 51: Experimental Setup for Peptide Mapping

    Slide 51: Experimental Setup for Peptide Mapping

    Experimental Setup for Peptide Mapping LC/MSE Reduction Therapeutic Proteins Reduced Peptide & Map Alkylation Denature & Alkylate LC/MSE Trypsin Digest Non-Reduced Peptide Map UNIFI Scientific Information System UPLC BEH300 C18, 1.7 µm, 2.1 x 100 mm ©2011 Waters Corporation 51

  52. Slide 52: UPLC/MSE Comprehensively Analyzes Complex Samples

    Slide 52: UPLC/MSE Comprehensively Analyzes Complex Samples

    UPLC/MSE Comprehensively Analyzes Complex Samples UPLC/MSE is a simple method of unbiased data acquisition that comprehensively analyzes all components in a single analysis. ©2011 Waters Corporation 52

  53. Slide 53: Surveying Chromatography and Complexity in Peptide Mapping Data

    Slide 53: Surveying Chromatography and Complexity in Peptide Mapping Data

    Surveying Chromatography and Complexity in Peptide Mapping Data Chromatogram 3D with Peak Chromatogram Assignments ©2013 Waters Corporation 53

  54. Slide 54: Peptide Mapping Data

    Slide 54: Peptide Mapping Data

    Peptide Mapping Data Assignments Annotated Chromatograms Fragment ions Spectrum ©2013 Waters Corporation 54

  55. Slide 55: Peptide Mapping Data

    Slide 55: Peptide Mapping Data

    Peptide Mapping Data Data Table (linked to Coverage Map) Coverage Map Assignments Fragment ions Spectra ©2013 Waters Corporation 55

  56. Slide 56: Access to both raw and processed data

    Slide 56: Access to both raw and processed data

    Access to both raw and processed data ©2013 Waters Corporation 56

  57. Slide 57: Case Study 1

    Slide 57: Case Study 1

    Case Study 1 ©2011 Waters Corporation 57

  58. Slide 58: Experimental Setup for Peptide Mapping

    Slide 58: Experimental Setup for Peptide Mapping

    Experimental Setup for Peptide Mapping Reduction Therapeutic Proteins & LC/MSE Alkylation Reduced Peptide Map Denature & Alkylate LC/MSE Non-Reduced Trypsin Digest Peptide Map UNIFI Scientific Information System UPLC BEH300 C18, 1.7 µm, 2.1 x 100 mm ©2011 Waters Corporation 58

  59. Slide 59: Equivalent protein coverage was obtained for innovator and biosimilar

    Slide 59: Equivalent protein coverage was obtained for innovator and biosimilar

    Equivalent protein coverage was obtained for innovator and biosimilar Innovator HC Innovator Biosimilar Biosimilar HC Innovator LC Biosimilar LC BEH, C18, 1.7 µm, 130, 2.1x 100 mm, Gradient 1 to 35% ACN, 0.05%TFA, 60 min ©2011 Waters Corporation 59

  60. Slide 60: Asp Isomerization of Peptide T24

    Slide 60: Asp Isomerization of Peptide T24

    Asp Isomerization of Peptide T24 (FNWYVDGVEVHNAK) Iso ASP XIC Isomerization: Asp to iso-Asp (no mass difference). Innovator isoAsp is not a natural amino acid and can potentially be immunogenic. Biosimilar ©2013 Waters Corporation 60

  61. Slide 61: Oxidation of HC Peptide T42

    Slide 61: Oxidation of HC Peptide T42

    Oxidation of HC Peptide T42 Biosimilar Batch I Innovator Batch % Oxidation I Sample Injections ©2013 Waters Corporation 61

  62. Slide 62: Peptide Maps Report

    Slide 62: Peptide Maps Report

    Peptide Maps Report: Report: Unifi enables researchers to focus on critical attributes of a molecule Analysis Information LC Coverage Innovator Batch I Biosimilar Batch % Oxidation I HC Coverage ©2011 Waters Corporation 62

  63. Slide 63: Experimental setup for disulfide bond mapping

    Slide 63: Experimental setup for disulfide bond mapping

    Experimental setup for disulfide bond mapping LC/MSE Reduction Therapeutic Proteins & Reduced Peptide Alkylation Map Denature & Alkylate LC/MSE Non-Reduced Trypsin Digest Peptide Map UNIFI Scientific Information System UPLC BEH300 C18, 1.7 µm, 2.1 x 150 mm ©2011 Waters Corporation 63

  64. Slide 64: Expected disulfide bonds in IgG1 Antibody Trypsin Digest

    Slide 64: Expected disulfide bonds in IgG1 Antibody Trypsin Digest

    Expected disulfide bonds in IgG1 Antibody Trypsin Digest IgG1 mAb contains 16 S-S bonds (12 Heavy chain intra, and 4 inter) VH –S – Digestion Enzyme: Trypsin -S -S –S – – –S -S Light chain -S –S CH – 1 – VL –S -S -S –S Symmetry of IgG1 molecule provides – – –S -S redundancy in mass-based search -S –

  65. Slide 65: Nonreduced peptide mapping enabled ID of all canonical S-S peptides

    Slide 65: Nonreduced peptide mapping enabled ID of all canonical S-S peptides

    Nonreduced peptide mapping enabled ID of all canonical S- S-S peptides A simple filter to only display disulfide containing peptides Disulfide Containing Peptides 2:T21-3:T21 MSE Fragment Ions 2:T21-3:T21 Additional 2:T21-3:T21 studies show there are no 2:T21-3:T21 scrambled disulfide presence 2:T21

  66. Slide 66: Disulfide Bonds Report

    Slide 66: Disulfide Bonds Report

    Disulfide Bonds Report Report:: Unifi enables researchers to focus on critical attributes of a molecule Component Plot for S-S peptides Analysis Information KK Disulfide containing peptides identified in both innovator and biosimilar mAb samples Component Summary ©2011 Waters Corporation 66

  67. Slide 67: Case Study 2

    Slide 67: Case Study 2

    Case Study 2 ©2013 Waters Corporation 67

  68. Slide 68: Automated Processing and Reporting with UNIFI: Intact Protein Analysis

    Slide 68: Automated Processing and Reporting with UNIFI: Intact Protein Analysis

    Automated Processing and Reporting with UNIFI™: Intact Protein Analysis INTACT PROTEIN ANALYSIS MaxEnt1 deconvoluted mass spectra in compare mode G0F/G1F G0F/G1F G1F/G1F G1F/G1F G0F/G0F G0F/G2F G0F/G0F G0F/G2F Innovator Innovator G1F/G2F G1F/G2F G2F/G2F G0/G0F G2F/G2F G0/G0F Biosimilar 1 Biosimilar

  69. Slide 69: Reduced Protein Analysis – LCs identical

    Slide 69: Reduced Protein Analysis – LCs identical

    Reduced Protein Analysis – LCs identical LC w/ PyQ HC Biosimilar 2 Reduction + Biosimilar 1 LC Innovator Mass Analysis of the Light Chain Light Chain MaxEnt1 deconvoluted mass spectra in compare mode Light Chain Innovator Innovator Biosimilar 2 Biosimilar 1 Automated Processing and Reporting Light c

  70. Slide 70: Reduced Protein Analysis of Heavy Chain

    Slide 70: Reduced Protein Analysis of Heavy Chain

    Reduced Protein Analysis of Heavy Chain G0F G1F MS Response Biosimilar 1 7.00E+06 Innovator 6.00E+06 Quantification of G0 G0F+K G2F 5.00E+06 C-terminal Lys G1F+K 4.00E+06 Variation G0 3.00E+06 Innovator 2.00E+06 Biosimilar 2 Biosimilar 1 1.00E+06 Summary plots 0.00E+00 1 2 3 4 5 6 7 8 9 Based on MS

  71. Slide 71: LC/MSE Tryptic peptide mapping to locate the sequence variance

    Slide 71: LC/MSE Tryptic peptide mapping to locate the sequence variance

    LC/MSE Tryptic peptide mapping to locate the sequence variance Tryptic Digest comparison between Innovator and Biosimilar 2 does not show sequence differences in Light Chain Light Chain - Innovator Compare mode Coverage Biosimilar 2 Map Automated Reporting ©2013 Waters Corporation 71

  72. Slide 72: LC/MSE Tryptic peptide mapping to locate the sequence variance

    Slide 72: LC/MSE Tryptic peptide mapping to locate the sequence variance

    LC/MSE Tryptic peptide mapping to locate the sequence variance Compare mode Heavy Chain - Innovator Biosimilar Coverage HC - Biosimilar 2 Map: shows section where no sequence match is made ©2013 Waters Corporation 72

  73. Slide 73: LC/MSE Tryptic peptide mapping to locate the sequence variance

    Slide 73: LC/MSE Tryptic peptide mapping to locate the sequence variance

    LC/MSE Tryptic peptide mapping to locate the sequence variance Heavy Chain - Innovator Compare mode Biosimilar 2 Coverage Map Alternative Enzyme to Trypsin needed to ascertain if there is a different sequence here in Biosimilar 2 ©2013 Waters Corporation 73

  74. Slide 74: LC/MSE Chymotryptic peptide mapping analysis of Biosimilar 2

    Slide 74: LC/MSE Chymotryptic peptide mapping analysis of Biosimilar 2

    LC/MSE Chymotryptic peptide mapping analysis of Biosimilar 2 Innovator Innovator Biosimilar 2 Biosimilar 2 BPI Peptide Map ∆m = 28 Da HC Coverage Map Chymotryptic Digest used to reveal differences – Peptides are highlighted in the coverage map as each is selected by the user Amino Acid Substitution

  75. Slide 75: UNIFI Peptide Map Workflow: MSE data confirming the sequence Variant

    Slide 75: UNIFI Peptide Map Workflow: MSE data confirming the sequence Variant

    UNIFI™ Peptide Map Workflow: MSE data confirming the sequence Variant Automated fragment K218 → R218 information from MSE data MSE Spectrum of chymotryptic digest confirms amino acid substitution – K for R at position 218 ©2011 Waters Corporation 75

  76. Slide 76: Summary of the Structural Analysis of Rituximab by LC/MS Approach

    Slide 76: Summary of the Structural Analysis of Rituximab by LC/MS Approach

    Summary of the Structural Analysis of Rituximab by LC/MS Approach The differences between Innovator and Biosimilars Rituximab candidates are: – Biosimilar 1 vs. Innovator – Biosimilar 2 vs. Innovator o Same AA Sequences o Sequence Variant in HC, K218 > R218 o Higher percentage of C- o Lower percenta

  77. Slide 77: Summary

    Slide 77: Summary

    Summary Intact Reduced Glycan Analysis Mass Analysis Peptide Mapping Reduced LC Non-Reduced Aggregate Analysis Mass Analysis Peptide Mapping Reduced HC Charge variant Mass Analysis Analysis ©2013 Waters Corporation 77

  78. Slide 78: 2013 Waters Biopharmaceutical Application Notebook

    Slide 78: 2013 Waters Biopharmaceutical Application Notebook

    2013 Waters Biopharmaceutical Application Notebook www.waters.com/ biopharmbook ©2013 Waters Corporation 78

  79. Slide 79: Thank You! Questions?

    Slide 79: Thank You! Questions?

    Thank You! Questions? Landing Page…http://www.waters.com/AUG20 – Promotional Discount Offers on Peptide Separation Columns – PDF Slide Deck – Full Webinar Recording of Today’s Session – Compilation of Literature, White Papers, Brochures General Questions – eMail: mychemrep@waters.com ©2013 Waters Co

Source: Internet Archive copy of waters.com

More decks from Waters Corporation

All 44 Waters decks